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Since the introduction of continuous ambulatory peri-
toneal dialysis (CAPD) during the late 1970s as a form
of home-based, self-care renal replacement therapy, peri-
toneal dialysis (PD) has become an appealing alternative
for the treatment of patients with end-stage renal dis-
ease (ESRD). A significant amount of research over the
last 25 years has resulted in continuous improvements in
the quality of PD treatment. Survival of patients on PD
is now at least as good as with hemodialysis, especially
during the first years of treatment, and results are grad-
ually improving. Considerable progress has been made
in understanding the nature of the interactions between
the dialysis solution and the peritoneal membrane, how
these interactions may result in structural alterations to
the membrane, and how peritoneal solute and fluid trans-
port are influenced by these alterations.
During recent years, as PD technique survival has im-
proved and peritonitis rates declined, PD researchers
have focused more attention on ways to improve the bio-
compatibility of dialysis solutions with the goal of extend-
ing the life of the peritoneum as a dialyzing membrane,
which may improve and extend the life of the PD patient.
The reason for this research focus is the observation that
the characteristic structural and functional alterations
to the peritoneal membrane during long-term PD treat-
ment may be the consequence of the continuous exposure
to solutions with high concentrations of glucose, glucose
degradation products (GDPs), and lactate, low pH, and
high osmolality. It is now clear that these alterations to
the peritoneal membrane may have a profound effect on
the well-being of the patient on long-term PD therapy.
According to the Consensus Conference on Biocom-
patibility held in 1994 [1], biocompatibility is “the ability
of a material, device or system to perform without a clin-
ically significant host response in a specific application.”
When applied to PD, biocompatibility refers to the ability
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of a solution formulation to permit adequate long-term
dialysis without a clinically significant undesirable host
response. Thus, biocompatibility refers to the effects of a
solution on the patient as a whole, systemically as well as
locally (intraperitoneally), which is the basis for the con-
cept of global biocompatibility. The fewer disturbances a
solution has on the structure, function, and homeostasis
of cells and tissues in the entire organism, the more glob-
ally biocompatible the solution is said to be. However,
until now little attention has been paid to the systemic
aspects of PD solution biocompatibility.
Use of a high concentration of bicarbonate as the so-
lution buffer instead of lactate, or a physiologic con-
centration of bicarbonate together with a markedly
reduced concentration of lactate provides a means to de-
liver glucose-based solutions at a physiologic pH [2, 3].
Such solutions have a composition that is closer to that of
the interstitial fluid, and may therefore be more biocom-
patible with respect to peritoneal cells, while at the same
time providing equivalent or better correction of acido-
sis. Furthermore, the dual-chambered bag used to deliver
these solutions has been designed to minimize the for-
mation of GDPs during heat sterilization. One compart-
ment contains electrolytes at a high pH, while the other
contains a high concentration of glucose at a low pH.
A growing long-term experience with these new dialysis
solutions indicates a favorable effect on peritoneal mem-
brane structure and function. In addition, there is an
increasing number of reports of observed and suggested
potential favorable systemic effects of these solutions
(Fig. 1, Table 1). This review will focus on the benefits be-
yond the membrane (i.e., the systemic benefits that may
be achieved with the new biocompatible PD solutions).
POTENTIAL HARMFUL SYSTEMIC EFFECTS
OF CONVENTIONAL PD SOLUTIONS
Conventional PD solutions have unphysiologic charac-
teristics, including low pH, high concentrations of lactate
and glucose, hyperosmolality, and a spectrum of GDPs
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Fig. 1. Potential mechanisms by which the use of a bicarbonate/lactate solution may have an impact on morbidity and mortality of peritoneal
dialysis (PD) patients.
formed during heat sterilization. These characteristics
have been shown separately or in combination to neg-
atively influence various aspects of peritoneal cell func-
tion [4–6]. Several in vitro, ex vivo, and in vivo studies,
recently reviewed by Stigant and Bargman [7], suggest
an association between cell toxicity and low pH, high lac-
tate, and GDPs. These studies are examined in detail in
other articles in this supplement. Much less information
is available on the systemic effects of conventional PD
solutions, although the clinical drawbacks of the use of
standard high lactate, glucose-based, acidic solutions in
PD are well recognized.
Metabolic and nutritional disturbances associated
with conventional glucose-based PD solutions
Glucose uptake from conventional PD solutions
may contribute to metabolic and nutritional alterations
such as hyperglycemia, hyperinsulinemia, anorexia, obe-
sity, and hyperlipidemia, although in malnourished pa-
tients the dialysis solution is a useful energy source.
These alterations may not be resolved by substitution
of bicarbonate-buffered or bicarbonate/lactate-buffered
solutions using glucose as osmotic agent, although it
was recently shown that bicarbonate-containing solu-
tions improve glycemic metabolic control in diabetic
patients [8]. In addition, whereas conventional PD is asso-
ciated with protein and amino acid losses that contribute
to malnutrition, there is substantial evidence that addi-
tion of amino acid–based solution may minimize this ef-
fect on nutritional status. As the focus of this review is
the new biocompatible low-lactate, glucose-based solu-
tions, the effects of dialysis fluids with alternative os-
motic agents will be only briefly addressed. However,
further discussion of these issues can be found elsewhere
[9].
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Table 1. Studies analyzing the systemic effects of new, more biocompatible PD solutions
Author [reference] Design Outcome
Carrasco et al 2001 [48] Randomized, controlled, open-label study
(bicarbonate/lactate vs. lactate)
Better acid/base correction with
bicarbonate/lactate solutions
Coles et al 1998 [36] Randomized, open-label, prospective, 2-month
trial (38 mmol/L bicarbonate vs. 25 mmol/L
bicarbonate plus 15 mmol/L lactate and
40 mmol/L lactate)
Better control of acidosis with bicarbonate
or bicarbonate/lactate
Cooker et al [abstract; Perit Dial Int
21:S18, 2001]
Six-month clinical study analyzing dialysate
effluent from PD patients (lactate-based vs.
bicarbonate/lactate–based solution)
Decreased IL-6 synthesis and VEGF
secretion based on effluent analysis at 3
and 6 months
Feriani et al 1998 [30] Twelve-week, randomized, controlled,
multicenter trial (34 mmol/L bicarbonate- vs.
35 mmol/L lactate-buffered PD solution)
Bicarbonate-buffered solution improved
correction of acidosis vs. lactate solution
le Poole et al [abstract; J Am Soc
Nephrol 13:200A, 2002]
Randomized, prospective, crossover,
multicentre trial in newly CAPD patients
(lactate-buffered vs. a combined solution
schedule: Physioneal, Nutrineal, Extraneal).
Combination therapy effective and
preserved renal residual function
Mactier et al 2002 [38] A randomized, double-blind, crossover study
(bicarbonate vs. bicarbonate/lactate solutions)
Bicarbonate/lactate solution caused less pain
on infusion than bicarbonate solution
Rippe et al 1997 [49] Clinical study combined with computer
simulations
Decreased discomfort/infusion pain with
new fluid; equal mass transfer coefficients;
and drained volumes
Sundaram et al 1997 [50] Clinical study (lactate vs. bicarbonate-lactate
solutions; 1.36 and 3.85% glucose)
Bicarbonate/lactate solution showed
significant improvement in phagocytosis in
peripheral blood
Tranaeus et al 2000 [39] Twelve-month, randomized, prospective,
controlled, open-label study
(bicarbonate/lactate vs. lactate-buffered PD
solutions)
Equivalent urea and creatinine clearances;
increased UF; decreased pain on infusion
Van Bree et al [abstract; J Am Soc
Nephrol 13:43A, 2002]
Prospective registry (12 countries, evaluations
every 6 months) analysis of patients treated
with alternative solutions
Bicarbonate/lactate solution associated with
decreased peritonitis duration and rate
Zheng et al 2001 [43] Animal model of oral intake Conventional PD solution suppressed oral
intake (degree increased with glucose
concentration)
Abbreviations are: PD, peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; UF, ultrafiltration; VEGF, vascular endothelial growth factor; IL-6,
interleukin-6.
Conventional PD solution factors affecting
the PD patient
Conventional high-lactate PD solutions have a low pH
and contain GDPs, two factors that potentially could act
as activators of local inflammatory response, production
of free radicals, and in the case of GDPs, generation of
advanced glycation end products (AGEs). Lactate, es-
pecially in high concentrations, also can contribute to
negative systemic side effects such as anorexia and lactic
acidosis.
One important question to ask is how great an effect
do conventional high-lactate, glucose-based, acidic PD
solutions have on the patient, apart from the local effects
on the peritoneum. First, it should be noted that there
are strong links between the PD solution, the peritoneal
membrane, and the status of the patient (Fig. 1). There-
fore, possible interactions between these 3 factors should
be addressed (Fig. 2). The most common functional alter-
ation to the membrane during long-term CAPD (perhaps
in response to the exposure of the peritoneum to solu-
tions with high lactate and glucose concentrations and
low pH) is an increase in peritoneal small solute transport
rate (PSTR) [10], which results in impaired ultrafiltration
and decreased dialysis efficiency [11]. Once ultrafiltra-
tion failure occurs, fluid balance becomes more difficult,
and volume overload develops. Since decreased ultrafil-
tration is a major risk factor for increased mortality in PD
patients [12], prevention of morphologic and functional
changes to the peritoneum represents an important tar-
get for increasing PD technique and patient survival. In
addition, a high PSTR in itself may represent an indepen-
dent risk factor for increased mortality, possibly because
of its association with both intraperitoneal and systemic
inflammation. The reasons for the detrimental effects of
a high PSTR are yet to be clarified [13].
Associations between local and systemic inflammation
One example of the importance of the interaction be-
tween the status of the peritoneum and the well-being
of the PD patient is the relationship between systemic
and local inflammation. Bioincompatible dialysis solu-
tions induce a chronic generation of inflammatory media-
tors in the peritoneal cavity. At the same time, it is known
that a persistent systemic inflammatory state is present
in many ESRD patients, both before and after initiation
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Fig. 2. The role of new peritoneal dialysis
(PD) solutions in enhancing global biocom-
patibility.
of dialytic treatment, which is often combined with mal-
nutrition and atherosclerosis (so-called MIA syndrome)
[14]. As circulating inflammatory mediators are strong
predictors of mortality in dialysis patients [15], it is
important to determine the extent to which local in-
traperitoneal inflammation contributes to systemic in-
flammation. On the other hand, it is also possible
that systemic inflammation leads to increased local
inflammation.
Dialysate levels of one inflammatory mediator, the
pleiotropic cytokine interleukin (IL)-6, correlate with the
concentration of glucose in the dialysis fluid [16], and
there is an inverse correlation between IL-6 levels and
achieved ultrafiltration when corrected for the osmolar-
ity of the infused fluid [16]. Moreover, we have recently
reported that high levels of both intraperitoneal and sys-
temic IL-6 are associated with high PSTR [17] and ox-
idative stress [abstract; Pecoits-Filho R, Perit Dial Int
23(Suppl 1):S10, 2003], and that dialysate and plasma
IL-6 levels increase with time on peritoneal dialysis [ab-
stract; Pecoits-Filho R, Perit Dial Int 23(Suppl 1):S10,
2003]. Interestingly, plasma IL-6, a surrogate marker of
systemic inflammation and a strong predictor of death
in peritoneal dialysis patients [15], was positively associ-
ated with its intraperitoneal counterpart, suggesting a link
between local and systemic inflammation during conven-
tional PD [abstract; Pecoits-Filho R, J Am Soc Nephrol
13:42A, 2002]. Although these data are preliminary and
the causal relationship is not clear, it could be hypoth-
esized that reducing intraperitoneal inflammation may
also reduce systemic inflammation. This interesting hy-
pothesis needs to be further addressed in future studies,
which should also consider the possibility that reduced
systemic inflammatory activity may ameliorate cardio-
vascular disease in ESRD and thereby significantly di-
minish the high cardiovascular morbidity and mortality
of PD patients.
Single GDPs or combinations of GDPs not only have
significant cytotoxic effects on peritoneal cell function
[18], but may also accelerate the formation of AGEs [19].
It has been suggested that more than 70% of AGE forma-
tion in dialysate may be a consequence of GDPs present
in fresh PD solutions [19], and thus, that AGE forma-
tion triggered by glucose-based PD solutions may be re-
lated to the presence of GDPs rather than to glucose itself
[20]. Significant amounts of AGEs can be detected in the
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peritoneal tissue of PD patients, and it has been suggested
that this amount increases with time on PD treatment and
possibly also with the accumulated glucose exposure [21].
This increase also is likely due more to exposure to GDPs
in the dialysis fluid than to dialysate glucose as such, al-
though AGEs in diet may contribute as well [22]. Fur-
thermore, it is possible that GDPs can be absorbed from
the peritoneal cavity into the circulation, as recently sug-
gested by Zeier et al [23]. If this is confirmed, strategies
to avoid intraperitoneal GDPs will also have a potential
role in preventing accumulation of plasma AGEs, which
could potentially reduce the cardiovascular harm caused
by these compounds.
Systemic effects of acid-base regulation during PD
As one of the main goals of dialysis treatment is to
normalize the acid-base balance of the body, an important
aspect of dialysis solutions is related to their ability to con-
trol acidosis, both locally and systematically. Metabolic
acidosis is a frequent complication of dialysis therapy,
particularly in hemodialysis patients. Known complica-
tions and consequences associated with the acidosis of
renal disease include increased protein catabolism,
bone lesions, depression of myocardial contractility, and
growth retardation [24]. Correction of the metabolic aci-
dosis in elderly patients with chronic renal failure resulted
in an improvement in nutritional status, as evaluated by
an increase in serum albumin and prealbumin levels [25].
The correction of acidosis in children with renal tubular
acidosis improves growth velocity [26]. Also, in acidotic
PD patients, an increase in lactate dialysate concentra-
tion resulted in a marked improvement in serum bicar-
bonate levels and several nutritional parameters after one
year, and this improvement was more pronounced when
a higher (40 vs. 35 mmol/L) lactate concentration was
used [27]. In a recent study, Walls et al [28] dissected
the possible mechanism(s) behind the effect of acidosis
on muscle catabolism, showing that patients with a bet-
ter correction of acidosis (using a PD solution with the
higher concentration of lactate) presented downregula-
tion of amino acid degradation and muscle proteolysis via
the ubiquitin-proteasome system. Interestingly, this study
also suggested that proinflammatory genes may be shut
down by the correction of acidosis, raising the possibil-
ity of links between acidosis and activation of the proin-
flammatory activity in ESRD patients that would favor a
more vigorous control of acidosis. As discussed in other
articles in this supplement, the ability to correct acido-
sis with the bicarbonate-buffered solutions is equivalent
or better than that of conventional lactate-based dialysis
solutions.
In light of the preceding discussion, it seems reasonable
to assume that individual factors of conventional dialysis
fluids, as well as combinations of factors, may be harm-
ful to the peritoneal membrane and to the PD patient as
a whole through local and systemic mechanisms, namely
the effects of low pH, high glucose concentration, hyper-
osmolarity, and the presence of GDPs. Interestingly, the
introduction of the new bicarbonate/lactate-buffered so-
lutions into clinical practice offers a healthier, more phys-
iologic option (particularly concerning pH and GDPs),
which will be discussed in the following section.
POTENTIAL SYSTEMIC BENEFITS OF
BICARBONATE/LACTATE-BUFFERED PD
SOLUTIONS
An obvious replacement for a low pH, high lactate-
buffered PD fluid is a bicarbonate-buffered solution, as
bicarbonate solutions can be manufactured to have a neu-
tral pH. In addition, bicarbonate is the body’s natural
buffering agent and thus is a natural buffer alternative
to lactate in PD solutions. Endogenous bicarbonate is
lost across the peritoneal membrane during the use of a
lactate-buffered PD solution. The lactate flux from the so-
lution into the patient not only compensates for metabolic
acid production but also for the loss of bicarbonate into
the dialysate effluent; thus, large buffer fluxes of lactate
are required to achieve a small gain in the control of
metabolic acidosis [2, 29].
Bicarbonate or bicarbonate/lactate solutions?
At the present time, a variety of new, potentially more
biocompatible PD fluids have been manufactured and are
available for clinical use in several countries. Different
pure bicarbonate solutions have been studied, including
a 34 mmol/L bicarbonate solution [30] and a 39 mmol/L
bicarbonate solution [31], and the results of these stud-
ies supported their efficacy and safety. One of the most
widely used solutions contains a mixture of bicarbonate
and lactate (B/L solution) at physiologic pH.
Based on in vitro and ex vivo data suggesting that a
B/L solution may be less cytotoxic than a pure bicar-
bonate PD fluid [32, 33], and the concern that a shift
to pure bicarbonate-buffered solutions might result in
unknown long-term risks, a solution suitable for clinical
practice containing a mixture of bicarbonate (25 mmol/L)
and lactate (15 mmol/L) (B/L 40) was developed. The
B/L 40 solution also is favored over pure bicarbonate-
buffered solutions because it is more stable, and because
a bicarbonate concentration of 40 mmol/L may result in
an elevated partial pressure of carbon dioxide that may
induce intracellular acidosis [34]. Owing to the difficulties
in heat-sterilizing bicarbonate in the presence of other
constituents of the dialysate, a double-bag system is used
and the two components are mixed just prior to inflow.
This heat-sterilizing technique results in markedly re-
duced levels of GDPs in the dialysis fluid [35].
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A parallel, randomized, open-label, prospective,
2-month trial with an optional 4-month extension was
undertaken to compare two bicarbonate-based PD so-
lutions, one containing 38 mmol/L bicarbonate and the
other the B/L 40 solution, with a control solution con-
taining 40 mmol/L lactate. Both the B/L 40 and the pure
bicarbonate solutions effectively corrected acidosis and
did not cause clinically significant alkalosis. There were
no changes in other blood biochemistry parameters mea-
sured in the peritoneal equilibration test or in measure-
ments of dialysis adequacy, and both solutions were well
tolerated. This study showed that either the bicarbonate
or the B/L 40 solution could be utilized effectively in pa-
tients undergoing chronic PD [36]. However, it has been
reported that the therapeutic value of the B/L solution
was superior to that of conventional lactate-buffered so-
lutions [32]. Coles et al [3] showed that bicarbonate is, in
molar terms, equipotent with lactate in correcting acido-
sis. In addition, Ottes et al [37] recently confirmed pre-
vious findings showing that a B/L solution allowed more
patients to be controlled within the normal venous bicar-
bonate range, and also sustained a statistically significant
fall in magnesium and reduced pain on infusion.
Benefits of B/L solutions on infusion pain
An important side effect of a low pH dialysis fluid
is pain on infusion. Patient discomfort may lead to dis-
continuation of PD treatment or a propensity to limit
the number of dialysate exchanges. Although one may
consider infusion pain as a sign of bioincompatibility be-
cause it reflects a local reaction to the fluid, it could be
also viewed as an important determinant of a systemic
response, since pain on infusion may have a significant
impact on quality of life and compliance with the pre-
scribed dialysis schedule. There is no doubt that compli-
ance and quality of life are very important goals of PD
treatment. Cumulative evidence indicates that the new
bicarbonate-buffered solutions offer an improvement in
this aspect. As an example, in a clinical study comparing
bicarbonate-, lactate-, and B/L-buffered PD solutions,
Mactier et al [38] have shown that although both a bi-
carbonate and a B/L solution were clearly effective in re-
ducing abdominal pain associated with solution infusion,
this effect was more striking for the B/L solution. Also, in
a prospective study randomly comparing patients using
B/L and conventional dialysis solutions, 40% of the B/L
group reported less infusion pain [39].
Overall benefits of B/L solutions: What have we
learned from clinical trials?
Bicarbonate- and lactate-buffered solutions may of-
fer several other systemic benefits, apart from the well-
established local ones (Fig. 1). Tranaeus et al [39]
reported on a long-term experience with B/L solutions
in a prospective, open-label, randomized, controlled trial
(conventional vs. B/L solution), and showed favorable ef-
fects on various clinical end points. The clinical end points
included dialysis adequacy, peritoneal equilibration test
results, ultrafiltration volume, acidosis control, and pa-
tient acceptance. Although some of these end points, such
as transport parameters and ultrafiltration, are directly
related to the local effects of dialysis solutions, they also
are (and perhaps more importantly) intimately related to
systemic issues, such as fluid overload and patient mor-
tality. Patients were randomized 2:1 to the B/L solution
and conventional high-lactate solution, respectively, and
then followed for 6 months. There were fewer dropouts in
the study group, with 58 of the original 70 patients in the
B/L group remaining at 6 months (33 at 12 months), and
30 of the original 36 in the lactate group at 6 months (11
at 12 months). Moreover, 23 patients wished to continue
the use of the B/L solution after completion of the study.
Another important preliminary finding of this long-
term follow-up study is the significant mean increase from
baseline in net peritoneal ultrafiltration of 150 mL/day in
the B/L group (five patients also spontaneously reported
improved ultrafiltration with the B/L solution). In addi-
tion, net 4-hour ultrafiltration on peritoneal equilibration
testing at 6 months was higher in the B/L group com-
pared to the control group. This study did not evaluate
the impact of improved ultrafiltration on fluid status or on
patient and technique survival, but it is clear from other
studies that improved ultrafiltration is a very important
goal of PD treatment [40]. These data are particularly rel-
evant in light of the recent findings of the ADEquacy of
peritoneal dialysis in Mexico (ADEMEX) study [41], in
which the increment of PD adequacy assessed using small
solute clearances was not a predictor of mortality. Rein-
forcing the important role of water and sodium removal
in PD patient outcome, Ates et al [12] showed that peri-
toneal removal of sodium and fluid are strong predictors
of mortality in PD patients, whereas small solute clear-
ances are not. Because adequate fluid and sodium balance
are crucial for the clinical outcome of patients on PD, the
preliminary observation of an improvement in net ultra-
filtration observed with the B/L solutions may represent
an important advantage to their use. As residual renal
function is important in preventing the development of
fluid overload, it is also important to keep in mind the
preliminary findings of a recent study showing that a reg-
imen low in glucose and GDPs was associated with better
preservation of residual renal function [abstract; le Poole
K et al, J Am Soc Nephrol 13:200A, 2002].
Improvement of immune function with B/L solutions
It is likely that a more biocompatible dialysis fluid will
allow better functioning of the immune defense system in
the peritoneal cavity, and this could result in a decrease
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in the incidence and severity of peritonitis. Interestingly,
preliminary results of studies on B/L solutions indicate
that the incidence of peritonitis was significantly reduced
compared to conventional PD solutions [abstract; Van
Bree M, J Am Soc Nephrol 13:43A, 2002]. Furthermore,
reduced intraperitoneal inflammatory activity has been
observed when a B/L solution is used [abstract; Cooker L,
Perit Dial Int 21:S18, 2001], and may possibly prevent not
only the inflammatory-driven changes to the peritoneal
membrane during long-term PD, but perhaps also reduce
systemic inflammation with potential cardiovascular and
nutritional benefits.
Metabolic and nutritional benefits of B/L solutions
The metabolic and nutritional advantages of the B/L
solutions are becoming increasingly evident. In a recent
study, Marshal et al [8] showed that use of the B/L dialysis
fluids was associated with clear improvement in 24-hour
glycemic control in diabetic PD patients. Furthermore,
use of these solutions in combination with icodextrin-
and amino acid–based solutions resulted in further im-
provement in glycemic control.
Another systemic aspect of different PD solutions that
warrants discussion is their effect on appetite. The study
by Tranaeus et al [39] described above showed that pa-
tients on the B/L solutions had an increase in body weight
compared with baseline of 1 kg at 6 months and 1.6 kg
at 12 months. Additionally, five patients in the B/L group
reported improved appetite and an enhanced sense of
well-being. Although several factors may contribute to
anorexia in PD patients, it is likely that absorption of the
osmotic agent as well as other substances from the PD
fluid may be involved. Using an animal appetite model,
we and others [42, 43] recently emphasized the develop-
ment of hypophagia induced by PD solutions. This finding
appears to occur mainly because of the utilization of nu-
trients (glucose and perhaps lactate) absorbed from the
solutions, but dialysate GDPs may also be of importance
in this regard.
The inhibition of appetite may be specific for each nu-
tritional constituent of the PD solution and not simply
an effect of hyperosmolality or large dialysate fill volume
[44]. Thus, both amino acid– and glucose-based solutions
may inhibit appetite, and the degree of appetite inhibi-
tion seems to be greater with a higher concentration of
glucose in the dialysis fluid. Furthermore, whereas the
B/L solution had less impact on appetite than the con-
ventional high-lactate, glucose-based solution, no impact
on appetite was observed when icodextrin was used as an
osmotic agent [43]. We also observed that GDPs in the
PD solution are also involved in the suppression of ap-
petite and that the degree of inhibition is proportional to
pH and glucose concentration during heat sterilization,
presumably because this may influence the formation of
GDPs [43]. Therefore, one may speculate that the con-
centration of nutrients such as glucose, amino acids, and
lactate in the solutions may play a key role in the regula-
tion of appetite. In addition, other factors such as pH and
hypertonicity may also be of importance. These studies
suggest that dialysate GDPs, perhaps more than hyper-
tonicity and glucose per se, may play a pivotal role in
appetite inhibition in PD [43]. Although the clinical rel-
evance of these experimental results needs further eval-
uation, it is possible that the B/L-buffered solutions may
offer an important advance in improving nutritional sta-
tus in PD patients. This is supported by the findings of
increased body weight, despite increased net peritoneal
ultrafiltration observed in patients using the B/L solutions
in the aforementioned study [39].
Another interesting area for future research is the po-
tential impact of B/L solutions on the metabolism of
leptin (through enhanced elimination or decreased pro-
duction), because this protein appears to have a signif-
icant impact on both appetite and energy expenditure
[45]. Marked hyperleptinemia and metabolic acidosis are
common findings in patients with chronic renal failure,
and leptin and acidosis may reduce food intake. Hyper-
leptinemia in ESRD may be masked by metabolic acido-
sis, and metabolic acidosis may inhibit leptin synthesis or
secretion [46, 47]. Therefore, correction of acidosis with
the use of a B/L solution might contribute to alterations in
nutritional status through the effects of leptin on appetite
and nutritional intake.
The role of new PD solutions on enhanced
systemic biocompatibility
For far too long, the concept of biocompatibility has
almost exclusively been focused on the local biocompat-
ibility effects of PD solutions, which have been exten-
sively studied using in vitro, ex vivo, and clinical study
designs. Although local biocompatibility and the need to
preserve the viability of the peritoneal membrane are of
crucial importance, the focus on the local effects of PD
solutions has diverted attention from another even more
important aspect of PD therapy, namely the systemic ef-
fects of PD solutions and particularly how they affect the
patient as a whole. We propose that evaluations of new
PD solutions should address the global biocompatibility
of the solutions (i.e., both the local and systemic aspects
of biocompatibility) (Fig. 2).
The role of combinations of PD solutions in
global biocompatibility
The introduction of new PD solutions has created a
strong solution portfolio that allows for substantial im-
provements in the quality of PD care. The combined
use of these new solutions (B/L, amino acid–based, and
icodextrin-based solutions) is likely to play an important
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role in enhancing the global biocompatibility of PD as a
therapy. This advanced solution portfolio provides impor-
tant systemic and local benefits, which should help slow
the progression of comorbidities by minimizing glucose
load, optimizing fluid balance, delivering 25% of daily
protein needs, improving dyslipidemia, reducing hyper-
tension, improving blood glucose control, improving im-
mune defense, and preserving residual renal function. In
the near future, several new studies will test the hypothe-
sis that there is a probable multiplier effect in this strategy,
by which the benefits of the combination of alternative
PD solutions can surpass the sum of the benefits of each
individual solution.
CONCLUSION
The introduction of the new biocompatible PD so-
lutions represents an important improvement for PD
therapy and will lead PD into a new era. First, these so-
lutions reduce the negative impact of high lactate, high
glucose, high GDPs, and low pH on peritoneal membrane
viability. If this local effect can prevent peritoneal mem-
brane alterations, which would otherwise lead to an in-
crease in peritoneal transport rate, the impact on clinical
outcome via improvements in fluid and solute removal
would likely be significant, and may reduce cardiovascu-
lar mortality.
In addition to these indirect effects of peritoneal mem-
brane function on systemic status, the new solutions may
well have more direct effects beyond the membrane, such
as reduced systemic inflammation, oxidative stress, high
glucose stress, improved nutrition, and improved immune
response, as well as more adequate metabolic status and
improved control of fluid status [51] (Fig. 1). Most proba-
bly, such effects would have a significant impact on mor-
bidity and mortality, which at present is mainly related
to cardiovascular and infectious diseases. Although it re-
mains to be verified that the more biocompatible fluids
will ultimately have a measurable impact on patient mor-
bidity and mortality, there is already sufficient evidence of
a positive impact on several secondary clinical end points
related to patient morbidity and mortality. Therefore, it
is likely these solutions will become the global standard
for PD treatment in the near future.
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